



ДНС / SNS  Друштво за неуронауке Србије / Serbian Neuroscience Society

31 May - 02 June
Belgrade Youth Center
Belgrade

Congress
Serbian Neuroscience Society

Book of Abstracts



8th CONGRESS OF SERBIAN NEUROSCIENCE SOCIETY with international participation

31 May – 2 June 2023. Belgrade, Serbia - BOOK OF ABSTRACTS

Published by:

Serbian Neuroscience Society
Bulevar despota Stefana 142, 11060 Belgrade, Serbia

Editors

Selma Kanazir and Danijela Savić

Assistant editors:

Anica Živković
Željko Pavković

Technical editor:

Anđela Vukojević

Graphic design:

Olga Dubljević, Irina Veselinović

Copyright © 2023 by Serbian Neuroscience Society and associates. All rights reserved. No part of this publication may be reproduced in any form without written permission from the publisher.

ISBN: 978-86-917255-4-9

Graphene Quantum Dots show protective effect in animal model of neuroinflammation

Jelena Tasić¹, Sašenka Vidičević Novaković¹, Željka Stanojević¹, Verica Paunović², Saša Petričević³, Tamara Martinović⁴, Tamara Kravić-Stevović⁴, Darko Ćirić⁴, Zoran Marković⁵, Aleksandra Isaković¹ Vladimir Trajković²

¹University of Belgrade, School of Medicine, Institute of Medical and Clinical Biochemistry, Belgrade, Serbia

²University of Belgrade, School of Medicine, Institute of Immunology, Belgrade, Serbia

³Galenika ad, Center for biomedical research, Belgrade, Serbia

⁴University of Belgrade, School of Medicine, Institute of Histology and Embryology, Belgrade, Serbia

⁵Institute of Nuclear Sciences Vinca, Belgrade, Serbia

Background: Experimental autoimmune encephalomyelitis (EAE) is one of the most studied model of neuroinflammation, used to test immunomodulatory and antiinflammatory drugs. Graphene quantum dots (GQD) are oval graphite two-dimensional sheets with a diameter <100 nm, one carbon atom thickness, with potential applications in biomedicine.

Objective: To investigate the potential protective effect of GQD in EAE model.

Methods: Female DA rats were immunized with spinal cord homogenate and Freund's complete adjuvant. GQD treatment (10 mg/kg, ip) was administrated during the inductive, effector and both phases of a disease. MAP kinase (MAPK) and Akt activity in popliteal lymph nodes (PLN) and CNS was determined by western blot. Quantitative PCR and flow cytometry were used to examine the expression of proinflammatory cytokines and specific transcription factors while infiltration of GQD in cells/tissues was detected by transmission electron microscopy. GQD anti-inflammatory/direct cytoprotective effect was analyzed on oligodendrocyte and neuron cell cultures by MTT assay. Data were analyzed by Mann Whitney test ($p < 0.05$ was considered as statistical significant difference).

Results: GQD administration, in all phases of EAE, significantly reduced clinical score of a disease. Clinical improvement correlates with increase in activity of ERK, p38 and Akt that is followed by reduction of Th1 cell response in PLN and infiltrated spinal cord T cells. Due to its capacity to infiltrate cells and tissues, GQD exhibits direct cytoprotective effect on CNS. Additionally, GQD reduced the expression of proinflammatory cytokines in ConA stimulated lymphocytes.

Conclusion: GQD alleviate EAE, through direct cytoprotective effect on CNS and inhibition of Th1 cell response.